CN119139298A - X842制剂 - Google Patents

X842制剂 Download PDF

Info

Publication number
CN119139298A
CN119139298A CN202411410163.7A CN202411410163A CN119139298A CN 119139298 A CN119139298 A CN 119139298A CN 202411410163 A CN202411410163 A CN 202411410163A CN 119139298 A CN119139298 A CN 119139298A
Authority
CN
China
Prior art keywords
solid dispersion
pharmaceutical formulation
carrier
formulation according
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411410163.7A
Other languages
English (en)
Chinese (zh)
Inventor
王建新
杨建刚
胡平生
路明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Shengnuo Pharmaceutical Technology Co ltd
Guizhou Shengnuo Biotechnology Co ltd
Original Assignee
Shanghai Shengnuo Pharmaceutical Technology Co ltd
Guizhou Shengnuo Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Shengnuo Pharmaceutical Technology Co ltd, Guizhou Shengnuo Biotechnology Co ltd filed Critical Shanghai Shengnuo Pharmaceutical Technology Co ltd
Publication of CN119139298A publication Critical patent/CN119139298A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202411410163.7A 2022-03-30 2023-03-23 X842制剂 Pending CN119139298A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2022/084214 WO2023184282A1 (en) 2022-03-30 2022-03-30 X842 formulation
CNPCT/CN2022/084214 2022-03-30
PCT/CN2023/083375 WO2023185624A1 (en) 2022-03-30 2023-03-23 X842 formulation
CN202380010889.9A CN117157059B (zh) 2022-03-30 2023-03-23 X842制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202380010889.9A Division CN117157059B (zh) 2022-03-30 2023-03-23 X842制剂

Publications (1)

Publication Number Publication Date
CN119139298A true CN119139298A (zh) 2024-12-17

Family

ID=81386826

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411410163.7A Pending CN119139298A (zh) 2022-03-30 2023-03-23 X842制剂
CN202380010889.9A Active CN117157059B (zh) 2022-03-30 2023-03-23 X842制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202380010889.9A Active CN117157059B (zh) 2022-03-30 2023-03-23 X842制剂

Country Status (8)

Country Link
US (1) US20260166014A1 (enExample)
EP (1) EP4499046A1 (enExample)
JP (1) JP2025511145A (enExample)
KR (1) KR20240165457A (enExample)
CN (2) CN119139298A (enExample)
AU (1) AU2023247528A1 (enExample)
MX (1) MX2024011716A (enExample)
WO (2) WO2023184282A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024230943A1 (en) * 2023-05-08 2024-11-14 Cinclus Pharma Holding AB (publ) Linaprazan glurate for treating gastroesophageal reflux disease (gerd)
WO2026032974A1 (en) 2024-08-05 2026-02-12 Cinclus Pharma Holding AB (publ) Formulation of linaprazan glurate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368006B1 (en) * 2001-02-13 2006-05-03 AstraZeneca AB Novel modified released formulation
US20050249799A1 (en) * 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
CN101513403A (zh) * 2008-02-21 2009-08-26 上海慧德医药科技有限公司 含有苯并咪唑类化合物的药物制剂
FI20086158A0 (fi) 2008-12-03 2008-12-03 Mikael Dahlstroem Imidatsopyridiinijohdannaiset
CN103301066B (zh) * 2012-03-15 2018-12-07 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
CN106279151A (zh) * 2015-06-26 2017-01-04 江苏太瑞生诺生物医药科技有限公司 5-(2-(8-((2,6-二甲基苄基)氨基)-2,3-二甲基咪唑并[1,2-a]吡啶-6-甲酰胺基)乙氧基)-5-氧代戊酸的固体形式及其制备方法
US20210330599A1 (en) * 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
WO2020101860A1 (en) 2018-11-16 2020-05-22 Cnh Industrial America Llc System and method for aligning arms of an agricultural header
EP4054537B1 (en) * 2019-11-04 2023-06-07 Cinclus Pharma Holding AB (publ) Oral formulation of x842
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
US20220002297A1 (en) 2020-07-02 2022-01-06 Cinclus Pharma Ag Polymorphs of x842

Also Published As

Publication number Publication date
WO2023184282A1 (en) 2023-10-05
AU2023247528A1 (en) 2024-09-26
US20260166014A1 (en) 2026-06-18
MX2024011716A (es) 2024-11-08
KR20240165457A (ko) 2024-11-22
CN117157059B (zh) 2024-09-13
WO2023185624A1 (en) 2023-10-05
CN117157059A (zh) 2023-12-01
EP4499046A1 (en) 2025-02-05
JP2025511145A (ja) 2025-04-15

Similar Documents

Publication Publication Date Title
TWI810243B (zh) 用於治療囊腫纖化症之醫藥組合物
CN101636152B (zh) 含有西洛他唑的控释制剂及其制备方法
CN117157059B (zh) X842制剂
CN104395322B (zh) 含有利福昔明和氨基酸的药用组合物、其制备方法和用途
CN105611918B (zh) 含有他达拉非的口腔崩解型膜制剂及其制备方法
CN112118830B (zh) 高活性剂载量的固体剂型
JP4977611B2 (ja) 新規な種類の界面活性剤様物質
CN111514142B (zh) 含硝羟喹啉前药的药物组合物及其制备方法和应用
CN115837010A (zh) 抗癌组合物
TW200848056A (en) Solid dispersion of a neurokinin antagonist
JP2004518708A (ja) 放出性が改良された新規な処方物
CN117337170A (zh) 包含(4s)-24-氯-4-乙基-73-氟-35-甲氧基-32,5-二氧代-14-(三氟甲基)-32h-6-氮杂-3(4,1)-吡啶-1(1)-[1,2,3]三唑-2(1,2),7(1)-二苯七蕃-74-甲酰胺的药物剂型
US10660963B2 (en) Pharmaceutical composition containing tacrolimus and preparation methods thereof
EP3811932A1 (en) Dosage form of apalutamide
JP2022512239A (ja) アモルファス固体分散体
KR20040101437A (ko) 고체 분산체 조성물
KR101823071B1 (ko) 텔미사르탄-함유 정제의 제조방법
HK40102489B (en) X842 formulation
HK40102489A (en) X842 formulation
CN119587482A (zh) 一种拉西地平膜控缓释微丸胶囊及其制备方法
JP7817367B2 (ja) 難溶性薬物の浸透圧ポンプ制御放出錠剤及びその製造方法
CN113950324A (zh) 微型软胶囊萘普生组合物
WO2016169534A1 (en) Solid forms of amorphous empagliflozin
KR100539706B1 (ko) 타크로리무스 및 장용성 고분자를 함유하는 고체분산체
BR112024019689B1 (pt) Formulação farmacêutica para administração oral, dispersão sólida, e, comprimido ou cápsula

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: 550008 Guizhou Province, Guiyang City, Guiyang National High-tech Industrial Development Zone, Gaoxin Science and Technology Park, China Western (Guiyang) High-tech Industrial Research and Development Base No. 1, 2, 3, 4 Building (3) 1 Unit 13 Floor 3 Room

Applicant after: Guizhou Shengnuo Biotechnology Co.,Ltd.

Applicant after: Shanghai Shengnuo Pharmaceutical Technology Co.,Ltd.

Address before: 550000 Guizhou Province, Guiyang City, National High-tech Industrial Development Zone Western R&D Base Building 3, 13th Floor

Applicant before: Guizhou Shengnuo Biotechnology Co.,Ltd.

Country or region before: China

Applicant before: Shanghai Shengnuo Pharmaceutical Technology Co.,Ltd.